Sagimet Biosciences (STU:0O2) Ending Cash Position : €72.43 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Ending Cash Position?

Sagimet Biosciences's Ending Cash Position for the quarter that ended in Dec. 2024 was €72.43 Mil.

Sagimet Biosciences's quarterly Ending Cash Position declined from Jun. 2024 (€89.15 Mil) to Sep. 2024 (€69.39 Mil) but then increased from Sep. 2024 (€69.39 Mil) to Dec. 2024 (€72.43 Mil).

Sagimet Biosciences's annual Ending Cash Position increased from Dec. 2022 (€0.15 Mil) to Dec. 2023 (€68.90 Mil) and increased from Dec. 2023 (€68.90 Mil) to Dec. 2024 (€72.43 Mil).

Sagimet Biosciences Ending Cash Position Historical Data

The historical data trend for Sagimet Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Ending Cash Position Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

56.47

50.21

0.15

68.90

72.43

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial												68.90	162.64	89.15	69.39	72.43

Sagimet Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sagimet Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	71.757	+	0.67000000000001
	=	72.43

Sagimet Biosciences's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	73.548	+	-1.121
	=	72.43

Sagimet Biosciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SGMT:USA 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines